Natco Pharma Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 — transcript filed; not yet summarisedQ4 FY26
Q4 FY26 earnings call
NATCO Pharma reported consolidated revenue of Rs 4,375.9 crores for FY26 versus Rs 4,784 crores last year, with net profit of Rs 1,418.5 crores against Rs 1,883.4 crores, as lenalidomide-related exclusivity revenue declined. Management guided to a decline in FY27 earnings to a base level of Rs 700-750 crores PAT on revenue of Rs 3,400-3,500 crores, citing the absence of major exclusivities in the coming year. The company discussed its semaglutide launch, South African associate Adcock Ingram, ongoing search for acquisitions, and plans to demerge its Crop Health Sciences business.